Navigation Links
Oramed Pharmaceuticals Announces Reverse Stock Split
Date:1/22/2013

JERUSALEM, January 22, 2013 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (OTCQB:ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that its previously announced one for twelve reverse stock split has become effective. As of the open of business on January 23, 2013, the shares of Oramed will be trading on a reverse split-adjusted basis on the OTCQB Market under the symbol "ORMPD," which replaces the previous symbol "ORMP" for the next 20 business days. Oramed effected the reverse stock split in order to help it meet the qualifications for listing its shares on the Nasdaq Capital Market.  

The reverse split reduces the number of shares of Oramed's authorized shares of common stock from approximately 200,000,000 to approximately 16,666,667 and outstanding shares common stock from approximately 86,505,020 to approximately 7,209,652. The exercise price and the number of shares of common stock issuable under Oramed's outstanding warrants and options have been proportionately adjusted to reflect the reverse stock split. Fractional shares created as a result of the stock split will be rounded up to the next whole share.

 "We are taking steps to move our company forward on many fronts and this reverse stock split puts us closer to our goal of up-listing to a major market in the U.S.," commented Oramed CEO, Nadav Kidron .

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin caps
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
2. Todays Research on Mylan and Watson Pharmaceuticals: One Drug Makers Sorrow is Another Ones Joy
3. Biscayne Pharmaceuticals Closes $1.5 Million Financing To Advance Recent Discoveries Of Pioneering Endocrine Drug Researcher
4. UPM Pharmaceuticals Enhances its Pre-Formulation Capabilities
5. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
6. Rafarma Pharmaceuticals, Inc. Achieves Full Certification
7. Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference
8. Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
9. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
10. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
11. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... ... orthopedic surgeon, Wade McKenna, DO, announced today that the use of sterile, dehydrated ... in complete healing of an otherwise non-healing surgical knee wound. , The case ...
(Date:8/27/2015)... 27, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") ... Biohaven Pharmaceutical Holding Company Limited (Biohaven), announced today ... study of BHV-0223, a glutamate modulating agent. Biohaven ... and recently obtained clearance from the U.S. Food ... testing. Portage holds 54% equity interest in Biohaven, ...
(Date:8/27/2015)... , August 27, 2015 GlassesOff (OTCBB: ... processing functions in the human vision system, announced today a ... point guard Chris Paul to develop a new ... want to improve their real-life on-court performance. Vision ... whether it is shooting a ball or blocking a pass. ...
(Date:8/26/2015)... ... August 26, 2015 , ... ... that a second US laboratory is to open in Manhattan, Kansas in early ... partnership and long-term growth of research and development through collaboration with researchers from ...
Breaking Biology Technology:Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3
... flowers: in the nineties of the last century Norwegian ... in petunias inhibited its activity instead of reinforcing it ... was found that the mechanism is based on the ... the late nineties the Nobel prizewinners Andrew Fire and ...
... deal with the same problems, but they use different ... be difficult, if not impossible., A new $2.9 million ... National Science Foundation (NSF), will help bridge this problematic ... common problems a range of scientists face., The grant ...
... Quest Diagnostics,Incorporated (NYSE: DGX ), the nation,s leading ... is scheduled to speak,at the 2007 UBS Global Life ... 2007. The Quest Diagnostics presentation is scheduled to,begin at ... webcast live during the conference and will be,available to ...
Cached Biology Technology:Mechanism for the in-vivo transport of siRNA 2Mechanism for the in-vivo transport of siRNA 3CCMR gets $2.9M for training grad students in nanoscale science 2Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference 2
(Date:8/5/2015)... -- According to a new market research ... Vertical (BFSI, Airport, IT & Telecom, Utilities, Education, Defense ... 2020", published by MarketsandMarkets, defines and segments the Physical ... The global PIAM Market is estimated to grow from ... at a CAGR of 14.9 % from 2014 to ...
(Date:8/4/2015)... 2015 Research ... the addition of the "Digital Forensics ... Sub-Segment (Computer Forensics, Network Forensics, Mobile Device ... Vertical and Region - Global Forecast to ... By Component (Hardware, Software, and Service), ...
(Date:7/31/2015)... , Kina, 31. juli 2015 Den ... bliver afholdt af BGI fra den 22. - 25. oktober ... Konferencen fejrer sin 10-års fødselsdag i år. Siden ... mest indflydelsesrige årlige møder på ,omik,-feltet, og er en ... ICG-10 fokuserer på nylige gennembrud og ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... hundreds, if not thousands, of suspected toxic substances every ... the brain, immune system, reproductive organs or hormones. Children ... requires product testing of most chemical compounds before they ... Riverside professor Carl Cranor argues in a new book, ...
... research effort designed to prevent the introduction of viruses to ... Chesapeake Bay watermen improve their bottom line by reducing the ... The findings, published in the journal Diseases of Aquatic ... in diseased and dying crabs likely occurs after the pre-molt ...
... scientists of the Technische Universitaet Muenchen (TUM) have been ... Prof. Stephan A. Sieber for the development of drugs ... million to study interactions between cellular components; 1.6 million ... a basic theory on elementary particles; Prof. Daniel Cremers ...
Cached Biology News:Legally poisoned 2Blue crab research may help Chesapeake Bay watermen improve soft shell harvest 2Nearly 10 million euros ($13.6 million) in ERC grants for 6 Technische Universitaet Muenchen researchers 2Nearly 10 million euros ($13.6 million) in ERC grants for 6 Technische Universitaet Muenchen researchers 3Nearly 10 million euros ($13.6 million) in ERC grants for 6 Technische Universitaet Muenchen researchers 4Nearly 10 million euros ($13.6 million) in ERC grants for 6 Technische Universitaet Muenchen researchers 5Nearly 10 million euros ($13.6 million) in ERC grants for 6 Technische Universitaet Muenchen researchers 6
Anti-DAP-1, Rabbit Monoclonal Immunogen: KLH-conjugated synthetic peptide corresponding to the C-terminal region of human DAP-1. Molecular Weight: 11 kDa Quality Assurance: Routinely eval...
Mouse monoclonal [TONI-1] to Angiotensin II Type 1 Receptor (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 185 SwissProtID: P30556...
1/4" to 1/8" Adapter for Reflectance Probe Holder...
... (GLP-1), C-terminal reactive. Cross-reacts fully with ... reactivity with the unamidated forms GLP-1(7-37) ... such as hGLP-2, glucagon, hGIP and ... is identical in all mammalian species ...
Biology Products: